Centre Hospital Region Metz Thionville

The nephrology team at Centre Hospital Region Metz Thionville is evaluating new strategies to slow kidney function loss in patients with biopsy‑confirmed IgA nephropathy. The study compares an established anti‑malarial drug with placebo to see if it can preserve glomerular filtration rate over several years.

• Assessing renal protection alongside standard RAAS inhibition
• Monitoring albuminuria as a marker of disease activity
• Evaluating long‑term safety of the investigational therapy

Findings could shape future guidelines for managing progressive kidney disease in France and beyond.

In the metabolic unit, researchers are testing a novel oral agent to reduce body weight in adults who are overweight or obese and have related health risks, but do not have type‑2 diabetes. The trial measures percentage change in weight after more than a year of treatment compared with placebo.

• Targeting weight loss without compromising metabolic health
• Assessing impact on comorbid conditions such as hypertension
• Collecting quality‑of‑life outcomes alongside physical measurements

Success may expand therapeutic options for weight management in European clinical practice.